| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | -0.23 | 0.03 |
| mRNA | PD-0332991 | GDSC1000 | pan-cancer | AAC | -0.074 | 0.03 |
| mRNA | MS-275 | FIMM | pan-cancer | AAC | -0.28 | 0.03 |
| mRNA | necrosulfonamide | CTRPv2 | pan-cancer | AAC | -0.086 | 0.03 |
| mRNA | BRD-K86535717 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.03 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.07 | 0.03 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.077 | 0.03 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.081 | 0.03 |
| mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | -0.065 | 0.04 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | -0.062 | 0.04 |